When you’re in critical negotiations, there’s nothing more valuable than insights. Large pharmaceutical brands within large markets can usually get their hands on competitive market insights. But sometimes — even for the big guys — it can be challenging to get an accurate read on their marketplace positioning within smaller emerging markets. It can also be hard to see the gaps in a product category and where opportunities lie ahead.
The vaccines business unit of a major pharma company approached Escalent under these conditions. Their vaccine showed the potential to protect millions of people in these countries. But they needed help bolstering their sales pitch to over 20 governing municipalities in emerging markets.
Escalent knows the APAC, AfME, and LATAM regions. These are markets where traditional information is lacking. However, our experience working with both blockbuster and smaller brands within these markets enabled us to get proxy information quickly. Our solution combined secondary research and in-depth interviews with regional experts. What we learned allowed our client to segment vaccine tenders by public and private markets within individual regions. We then assessed key tenders, pricing trends, and localized nuances.
This helped our client identify existing markets at risk because of misaligned pricing strategies. Our efforts also helped our client prioritize entry into new high-demand markets based on GNI per capita and other macroeconomic factors.
Armed with hard-to-find intelligence, our client was able to successfully negotiate and renew existing tenders. With favorable pricing structures, they advanced to the shortlist of government vaccine providers in emerging markets.
Escalent specializes in uncovering hard-to-find insights for Health and Life Sciences. We’ll get you the answers you need to tell your story and make confident decisions.
With affluent investors across all age and wealth cohorts consolidating the number of relationships they have with both mutual fund and ETF providers, wealth management firms have an opportunity to win additional investor assets.
Data from the latest Cogent Syndicated report reveal the need for continued innovation in retirement income solutions to help participants traverse the decumulation phase.
Escalent’s technology experts explore how understanding the origins of generative artificial intelligence (AI) can help tech companies effectively strategize on integrating generative AI into their business and offerings for maximum customer impact